Inclusion Criteria

• ≥2 years old at visit 1, with a diagnosis of blepharitis confirmed by the Investigator
• Subjects <18 years old must be able to be examined at the slitlamp (handheld) without systemic anesthesia
• A self-reported history of ≥1 previous episode of blepharitis
• Adult subjects must provide verbal and written informed consent; for subjects <16 years old, a parent or legal guardian must provide written informed consent and sign the HIPAA form* (or equivalent, if applicable); whenever practical and appropriate per local requirements, a child's assent should also be sought before inclusion
• Have not responded adequately to lid hygiene in the past (self-reported)
• CDVA ≥0.7 LogMAR in each eye, assessed with the ETDRS chart^†
• Able to comply with the protocol requirements, including the ability to self-administer or receive topical treatment BID to their eyelid margins
• Literate and able to complete questionnaires independently, or in the case of pediatric patients, can comprehend the questionnaires with the help of a parent/guardian or interviewer
• Women of childbearing potential must have a negative urine pregnancy test at visit 1 and be willing to use an adequate method of contraception throughout the study and 30 days from the last study treatment application

The use of MR-139 for Blepharitis is currently being investigated and its safety and efficacy have not been established.
*Approved by the appropriate Institutional Review Board/Ethical Committee; ^†Subjects may be refracted if needed.
BID, twice daily; CDVA, corrected distance visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; HIPAA, Health Insurance Portability and Accountability Act; LogMAR, logarithm of the minimum angle of resolution.
https://clinicaltrials.gov/study/NCT06400511.

Exclusion Criteria

• Received a COVID vaccination or recovered from COVID-19 symptoms <1 week prior to baseline visit
• A history of or active herpetic or neurotrophic keratitis
• Abnormal eyelid anatomy (other than due to blepharitis) that might adversely affect clinical signs and symptoms,* including but not limited to lagophthalmos, malposition of the eyelid, or tumor(s) of the eyelid or eyelid margin
• Received other treatments for blepharitis within 30 days of visit 1
• Known hypersensitivity to study medications or any diagnostic agents to be used in the study
• Currently enrolled in an investigational drug or device study or used an investigational drug or device within 30 days prior to the baseline visit and during the treatment period
• Subjects unable to adhere to the study protocol*

The use of MR-139 for Blepharitis is currently being investigated and its safety and efficacy have not been established.
*In the opinion of the Investigator.
COVID, coronavirus disease.
https://clinicaltrials.gov/study/NCT06400511.

• Complete resolution (score 0 on the grading scale of 0–4*) of eyelid debris at week 6

The use of MR-139 for Blepharitis is currently being investigated and its safety and efficacy have not been established.
*A higher score indicates a worse outcome.
https://clinicaltrials.gov/study/NCT06400511.

This clinical trial does not currently have results